TRASTUZUMAB-ANNS
Manufacturer: Amgen Inc
Score: 144.0
Kanjinti (Trastuzumab-anns) is a humanized IgG1 kappa monoclonal antibody used for the treatment of HER2-overexpressing breast cancer and metastatic gastric or gastroesophageal junction adenocarcinoma. It works by selectively binding to the extracellular domain of the HER2 protein, inhibiting the proliferation of human tumor cells that overexpress HER2. The most common adverse reactions include fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia. Important safety information includes the risk of cardiomyopathy, infusion reactions, embryo-fetal toxicity, and pulmonary toxicity. The recommended dose for adjuvant treatment of HER2-overexpressing breast cancer is 4 mg/kg over 90 minutes IV infusion, then 2 mg/kg over 30 minutes IV infusion weekly for 12 weeks, followed by 6 mg/kg over 30-90 minutes IV infusion every three weeks. For metastatic HER2-overexpressing breast cancer, the initial dose is 4 mg/kg as a 90-minute IV infusion, followed by subsequent weekly doses of 2 mg/kg as 30-minute IV infusions. Special population considerations include use during pregnancy, nursing mothers, pediatric use, and geriatric use.
Cardiomyopathy, infusion reactions, embryo-fetal toxicity, and pulmonary toxicity
Dose adjustments may be necessary for patients with cardiac dysfunction or infusion reactions
4 mg/kg over 90 minutes IV infusion, then 2 mg/kg over 30 minutes IV infusion weekly for 12 weeks
Not established
4 mg/kg as a 90-minute IV infusion, followed by subsequent weekly doses of 2 mg/kg as 30-minute IV infusions
Not established